Provided by Tiger Trade Technology Pte. Ltd.

INDIVIOR PLC

36.87
-0.9100-2.41%
Post-market: 36.890.0200+0.05%19:59 EDT
Volume:2.50M
Turnover:92.77M
Market Cap:4.35B
PE:13.33
High:38.52
Open:37.68
Low:36.70
Close:37.78
52wk High:42.81
52wk Low:22.22
Shares:118.00M
Float Shares:109.00M
Volume Ratio:1.35
T/O Rate:2.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.77
EPS(LYR):1.64
ROE:12.20%
ROA:26.40%
PB:-20.92
PE(LYR):22.48

Loading ...

Indivior Pharmaceuticals Inc: Supernus Must Pay Co Termination Fee of $101 Mln if the Merger Agreement is Terminated Under Certain Circumstances

THOMSON REUTERS
·
Aug 03

Indivior Pharmaceuticals Beats Q2 Revenue on Sublocade Growth, Raises FY Guidance

Reuters
·
Aug 03

GUIDANCE: (INDV) Indivior Expects 2026 Net Revenue Range $1.30B - $1.37B, vs. FactSet Est of $1.26B

MT Newswires Live
·
Aug 03

Supernus Q2 FY26 Net Loss Widens to $58.4 Million; Revenue Rises 32% to $219.1 Million

Reuters
·
Aug 03

Indivior Q2 Adj. EPS $1.15 Beats $0.87 Estimate, Sales $343.000M Beat $307.550M Estimate

Benzinga Earnings
·
Aug 03

Supernus Pharmaceuticals Shares Rise 5.3% Premarket After Co to Merge with Indivior Pharmaceuticals

THOMSON REUTERS
·
Aug 03

Indivior Q2 FY26 GAAP Net Income Rises to $122 Million; Revenue Increases 14% to $343 Million YoY

Reuters
·
Aug 03

Indivior Pharmaceuticals Q2 Revenue USD 343 Million Vs. IBES Estimate USD 307.6 Million

Reuters
·
Aug 03

Indivior Pharmaceuticals Outlook FY Revenue USD 1,295-1,365 Million

THOMSON REUTERS
·
Aug 03

Press Release: Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance

Dow Jones
·
Aug 03

Supernus, Indivior Agree All-Stock Merger, Combined Firm to Trade as Supernus on NASDAQ

Reuters
·
Aug 03

Supernus Pharmaceuticals - Stockholders Will GET 1.5401 Common Shares of Indivior Pharmaceuticals for Each Share of Supernus Pharmaceuticals They Own

THOMSON REUTERS
·
Aug 03

Supernus Pharmaceuticals Inc: Indivior Pharmaceuticals Stockholders Will Own Approximately 56.5% of Combined Company

THOMSON REUTERS
·
Aug 03

Supernus: Combined Co Expected to Benefit from Immediate Scale and $125 Mln of Expected Annual Cost Synergies

THOMSON REUTERS
·
Aug 03

Supernus: Indivior Pharmaceuticals Stockholders to GET One-Time Special Cash Dividend of $1 Bln in Aggregate Immediately Prior to Closing of Merger

THOMSON REUTERS
·
Aug 03

Supernus Pharmaceuticals Inc - Definitive Agreement to Combine in a Tax-Free All-Stock Merger

THOMSON REUTERS
·
Aug 03

Supernus Pharmaceuticals Inc - Combined Entity to be Named Supernus, Inc. and Jack Khattar to Serve as President and Chief Executive Officer

THOMSON REUTERS
·
Aug 03

Earning Preview: INDIVIOR PLC Q2 revenue is expected to increase by 25.79%, and institutional views are bullish

Earnings Agent
·
Jul 29

Indivior to Report Q2 2026 Results, Host Webcast Presentation

Reuters
·
Jul 23

Rxsight Names Aziz Mottiwala CEO, Ron Kurtz to Become Chief Medical Officer

Reuters
·
Jul 16